PDCD1 and nonpapillary renal cell carcinoma: Due to the high immunogenicity and strong T cell infiltration of RCC,5, 6 programmed cell death‐1/ programmed cell death‐ligand 1 (PD‐1/PD‐L1) monoclonal antibodies (mAbs), which can strengthen cellular immunity, have been gradually applied in the treatment of aRCC as monotherapy recently and achieved considerable efficacy and acceptable safety, especially in ccRCC.7